Kyowa Kirin Announces Discontinuation for Developing KHK2375 (Entinostat)
October 7, 2021
Tokyo, Japan, 7 October 2021 --Kyowa Kirin Co., Ltd. (TSE:4151, President and CEO: Masashi Miyamoto, ”Kyowa Kirin”) announces today the discontinuation for developing KHK2375 (generic name: entinostat).
KHK2375 is a Class I selective histone deacetylase (HDAC) inhibitor, which was discovered by Syndax Pharmaceuticals Inc. Kyowa Kirin signed a license agreement with Syndax Pharmaceuticals Inc. for the exclusive rights to the development and commercialization of KHK2375 in Japan and Korea in 2014.
Under the license agreement, Kyowa Kirin developed KHK2375 for indications of breast cancer in its territory. However, concerning the situation carefully, Kyowa Kirin discontinued KHK2375 development project.
Yoshifumi Torii, Ph.D., Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin commented, "We are disappointed in this decision, as it was expected to have novel possibilities in breast cancer treatment, especially in endocrine therapy. We would like to express our appreciation to all the patients and investigators who contributed to the clinical studies and our development and continue to push forward to deliver therapies that meet unmet medical needs in oncology.”
The Kyowa Kirin Group companies strive to contribute to the health and well-being of people around the world by creating new value through the pursuit of advances in life sciences and technologies.
